Free shipping on all orders over $ 500

Tabituximab barzuxetan

Cat. No. M24733
Tabituximab barzuxetan Structure
Synonym:

OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tabituximab barzuxetan (OTSA101-DTPA-90Y) is a radioimmunoconjugate composed of a humanized monoclonal antibody targeting FZD-10 (OTSA-101), and labeled with Yttrium 90. Tabituximab barzuxetan shows antineoplastic activity. Tabituximab barzuxetan can be used for synovial sarcoma research.

Chemical Information
CAS Number 1612758-88-9
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Related Wnt/beta-catenin Products
Fz7-21

Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove.

FZD7 antagonist 1

FZD7 antagonist 1 (peptide 34) is a dFz7-21 analogue.

NLS-StAx-h

NLS-StAx-h is a selective, cell permeable, stapled peptide Wnt signaling inhibitor with an IC50 of 1.4 μM.

Zamaporvint

Zamaporvint is an orally active, selective Wnt inhibitor that targets the membrane-bound o-acyltransferase porcupine and inhibits Wnt ligand palmitoylation, secretion and pathway activation. In addition, Zamaporvint displays potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines. It can be used in cancer-related studies.

Foxy-5

Foxy-5, a WNT5A agonist and a mimetic peptide of WNT5A, triggers cytoplasmic free calcium signaling without affecting β-catenin activation and inhibits migration and invasion of epithelial cancer cells.Foxy-5 effectively reduces metastatic spread of prostate cancer cells with low WNT5A expression in an in situ mouse model.

  Catalog
Abmole Inhibitor Catalog




Keywords: Tabituximab barzuxetan, OTSA101-DTPA; OTSA101-DTPA-90Y; OTSA101-SS01 supplier, Wnt/beta-catenin, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.